Benralizumab
CAS No. : 1044511-01-4
(Synonyms: MEDI-563; BIW-8405; KHK4563)
| Size | Price | Stock |
|---|---|---|
| 1mg | $880 | In-stock |
| 2mg | $1450 | In-stock |
| 5 mg | Get quote | |
| 10 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-P9923 |
| M.Wt: | 1000.00 |
| Formula: | N/A |
| Purity: | >98 % |
| Solubility: | H2O |
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma[1].
IC50 & Target:IL-5Ra/ CD125
In Vitro:Benralizumab (MEDI-563) binds to recombinant human and cynomolgus monkey IL-5Rα extracellular domains with a dissociation constant of 11 and 42 pM, respectively[2].
Benralizumab (1 pM-100 nM, 48 h) inhibits IL-5–induced proliferation of CTLL-2 cells transfected with recombinant human IL-5Rαβ with an IC50 of 0.3 nM[2].
Benralizumab binds only to the constructs containing human IL-5Rα D1[2].
Benralizumab mediates ADCC (antibody-dependent cell-mediated cytotoxicity) of human eosinophils and basophils with EC50s of 0.9 pM and 0.5 pM, respectively, and mediates eosinophil apoptosis[2].
In Vivo:Benralizumab (MEDI-563) (0-30 mg/kg; i.v.; once every 3 weeks for 12 weeks) reduces peripheral blood and bone marrow eosinophil[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Benralizumab
- Cat. No.:
- HY-P9923
- Quantity:
Your information is safe with us.